Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Issuance of U.S. Patent No. 11,197,906 Covering OKYO Pharma\u2019s Drug Candidate OK-101 for Use to Treat Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to Treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Prices $5.3 Million Offering of ADSs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease Is Now Listed on The ClinicalTrials.gov Public Website","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Proposed Public Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Tufts Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (\u201cNCP\u201d) Following Announcement of Clinical Trial Agreement with Tufts Medical Center","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Withdrawal of Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to Treat Dry Eye Disease (\u201cDED\u201d)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to Treat Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Public Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Withdrawal of Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (\"DED\")","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (\u0153NCP\u009d)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"$5.8 million","newsHeadline":"OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease Including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by OKYO Pharma

    Menu

    OKYO Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              OKYO Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease Including Ocular Pain Relief in its First-in-...

              Details:

              OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye. It is being evaluated for the treatment of Dry Eye Disease.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

              Details:

              OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, which is being evaluated for the treatment of neuropathic corneal pain.

              Lead Product(s): OK-101

              Therapeutic Area: Neurology Product Name: OK-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients wi...

              Details:

              OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye. It is being evaluated in phase 2 clinical trials for the treatment of Dry Eye Disease.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

              Details:

              OK-101 is a ChemR23 GPCR agonist, peptide drug candidate, which is currently under clinical development for the treatment of patients suffering from Dry eye disease.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

              Details:

              OKYO intends to use the net proceeds primarily for clinical development of the Company’s product candidates including, OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, to treat ocular diseases.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $5.8 million Upfront Cash: $5.8 million

              Deal Type: Public Offering October 31, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (œNCP)

              Details:

              OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response to treat Neuropathic Corneal Pain.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: IND Enabling Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")

              Details:

              OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is developed using a membrane-anchored-peptide (MAP) technology and shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

              Details:

              OKYO intends to use the net proceeds from the Offering primarily for clinical development of the Company’s product candidates, including OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $4.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

              Details:

              OKYO intends to use the net proceeds from the Offering primarily for clinical development of the Company’s product candidates, including OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Freedom Capital Markets

              Deal Size: $3.9 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OKYO Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OKYO Pharma Limited Announces Withdrawal of Public Offering

              Details:

              OKYO intends to use the net proceeds from the Offering primarily for clinical development of the Company’s product candidates, including OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

              Lead Product(s): OK-101

              Therapeutic Area: Ophthalmology Product Name: OK-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Freedom Capital Markets

              Deal Size: $3.9 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY